Revolution Medicines and AI company Iambic Therapeutics announced a multi-year collaboration leveraging Iambic’s NeuralPLexer AI platform for protein-ligand interaction prediction to accelerate discovery of novel oncology drug candidates. The agreement includes milestone and research funding totaling up to $25 million. Iambic’s AI will utilize Revolution’s proprietary structural and molecular data to enhance model performance, while both firms retain rights to exclusive targets. This partnership exemplifies growing integration of machine learning tools in precision drug design, aiming to tackle challenging cancer targets and expedite discovery timelines.